Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

Exclusion Criteria

• •Age \<18
• •Recent changes (previous 3 months) in HF maintenance medications (beta-blockers, angiotensin converting enzyme \[ACE\] inhibitors, aldosterone antagonists, vasodilators, cardiac glycosides, diuretics)
• •Hospitalization for worsening Heart Failure (HF) or acute decompensated HF within the previous 12months
• •Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable cardioverter defibrillator (AICD)
• •Angina or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing
• •Active infection including chronic infection
• •Active cancer
• •Recent (\<14 days) use of anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs \[NSAIDs\]), Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus), malignancy, or any comorbidity limiting survival or ability to complete the study
• •Pregnancy (determined by urine pregnancy test in women of childbearing potential)
• •Inability to give informed consent
• •Other conditions limiting completion of cardiopulmonary exercise test or completion of the study